Abstract
Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Current Drug Discovery Technologies
Title:NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease
Volume: 12 Issue: 4
Author(s): C. Subathra Devi, V. Mohanasrinivasan, C. George Priyadoss, Nikhil Arora, Bharti Singh, Neetu Mittal, Shubham Agarwal and Shwetank Saxena
Affiliation:
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Abstract: Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Devi Subathra C., Mohanasrinivasan V., Priyadoss George C., Arora Nikhil, Singh Bharti, Mittal Neetu, Agarwal Shubham and Saxena Shwetank, NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease, Current Drug Discovery Technologies 2015; 12 (4) . https://dx.doi.org/10.2174/1570163813666151117121210
DOI https://dx.doi.org/10.2174/1570163813666151117121210 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment
Current Drug Abuse Reviews Meet Our Editorial Board Member:
Current Alzheimer Research Properties of Neurotoxic Peptides Related to the Bri Gene
Protein & Peptide Letters Influence of Hypertension, Alone and in Combination with Other Vascular Risk Factors on Cognition
CNS & Neurological Disorders - Drug Targets Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Structural Neuroimaging Findings in Major Depressive Disorder Throughout Aging: A Critical Systematic Review of Prospective Studies
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Cognition Therapeutics (Guest Editor: Miao-Kun Sun)]
Current Drug Targets - CNS & Neurological Disorders Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Uncoupling Protein-2 and the Potential Link Between Metabolism and Longevity
Current Aging Science Clinical and Forensic Signs Related to Cocaine Abuse
Current Drug Abuse Reviews Imaging Epigenetics in Alzheimer’s Disease
Current Pharmaceutical Design Pharmacophore-based Drug Design of Novel Potential Tau Ligands for Alzheimer's Disease Treatment
Current Physical Chemistry Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Juvenile Neuronal Ceroid-Lipofuscinosis (Batten Disease): A Brief Review and Update
Current Molecular Medicine Rheumatological Manifestations in Diabetes Mellitus
Current Diabetes Reviews Evaluation of In Vivo and In Vitro Antimicrobial Activities of a Selective Serotonin Reuptake Inhibitor Sertraline Hydrochloride
Anti-Infective Agents